利用循环游离线粒体DNA片段组学特征实现非小细胞肺癌的精准早期诊断
该多中心研究分析了2306份血浆样本的ccf-mtDNA片段组学特征,构建了良恶性肺病鉴别(DBM)和NSCLC早期诊断(EDL)模型。DBM模型在3个验证队列中AUC超过0.9551,对小于1 cm的小结节AUC达0.9151;EDL模型检测0-I期NSCLC的AUC超过0.9759。研究表明ccf-mtDNA片段组学可作为NSCLC无创早期诊断的新策略。
要点
- ccf-mtDNA片段组学模型可高精度鉴别NSCLC与良性肺病,AUC超过0.9551。
- DBM模型对小于1 cm的小结节仍保持AUC 0.9151的诊断性能。
- EDL模型检测0-I期NSCLC的AUC超过0.9759,有助于早期发现。
核心结论
- 基于ccf-mtDNA片段组学的多中心研究为NSCLC的良恶性鉴别和早期诊断提供了新的无创方法。
研究设计与样本
- 研究分析了来自3家医院的2306份血浆样本的捕获-based ccf-mtDNA测序数据,包括1357例NSCLC患者、432例良性肺病患者和517例健康对照。
- 利用ccf-mtDNA片段组学特征构建了良恶性肺病鉴别(DBM)模型和NSCLC早期诊断(EDL)模型。
主要发现
- NSCLC患者的ccf-mtDNA片段组学特征与良性肺病患者及健康对照相比存在显著异常。
- DBM模型在3个验证队列中区分NSCLC与良性肺病的AUC超过0.9551,优于血清生物标志物。
- DBM模型对小于1 cm的小结节诊断AUC达0.9151。
- EDL模型检测0-I期NSCLC的AUC超过0.9759。
关键数值与推荐
- DBM模型在3个验证队列中鉴别NSCLC与良性肺病的AUC超过0.9551。
- DBM模型对小于1 cm小结节的诊断AUC为0.9151。
- EDL模型检测0-I期NSCLC的AUC超过0.9759。
临床怎么用
- ccf-mtDNA片段组学模型可用于辅助鉴别肺结节良恶性,减少良性病变患者不必要的侵入性操作。
- 该模型有助于避免NSCLC患者治疗延迟,并可辅助0-I期NSCLC的早期检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early differential diagnosis of benign and malignant lung diseases (DBM) is a critical challenge in the clinical oncology of non-small cell lung cancer (NSCLC). We aim to develop a novel strategy utilizing circulating cell-free mtDNA (ccf-mtDNA) fragmentomics for accurate and early diagnosis of NSCLC. METHODS: We analyzed capture-based ccf-mtDNA sequencing data of 2306 plasma samples from 1357 NSCLC patients, 432 benign lung diseases (BLD) patients, and 517 healthy controls (HCs) obtained from 3 hospitals. Subsequently, using ccf-mtDNA fragmentomic features, we developed models for DBM and Early Diagnosis of NSCLC (EDL). RESULTS: Our analysis revealed significantly aberrant fragmentomic features of ccf-mtDNA in NSCLC patients compared with those in BLD patients and HCs. Remarkably, the DBM model demonstrated remarkable capability to distinguish NSCLC from BLD, outperforming serum biomarkers with an AUC exceeding 0.9551 in 3 validation cohorts. Still, the DBM model exhibited superior diagnostic performance even for small nodules (<1 cm), achieving an AUC of 0.9151. Moreover, the DBM model demonstrated precise clinical management ability of pulmonary lesions, thereby avoiding unnecessary invasive procedures in BLD patients and preventing delayed treatment in NSCLC patients. Furthermore, the EDL model demonstrated outstanding performance in detecting stage 0-I NSCLC, with an AUC exceeding 0.9759. CONCLUSIONS: Our multicenter study provides a novel non-invasive approach using ccf-mtDNA fragmentomics for the DBM and early diagnosis of NSCLC, with potential applications in clinical decision-making in the management of NSCLC.
引用
- Peng F, Wang S, Jiao H, et al. Accurate and early diagnosis of non-small cell lung cancer using aberrant fragmentomic features of circulating cell-free mitochondrial DNA. Am J Respir Crit Care Med. 2026. PMID: 40961284. doi:10.1164/rccm.202411-2247OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。